StockData
Kazia Therapeutics Ltd logo

Kazia Therapeutics Ltd (KZIA) stock

KZIANasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Jun 30, 2025Last filing: 20-F on Nov 17, 2026Score 1/30
$5.31−0.29 (-5.18%)

Close on Nov 17, 2026Market cap $8.60MP/E –Yield –

Kazia Therapeutics Ltd saw revenue fall 98.2% to A$42.00K over fiscal 2025. At the latest close the market valued the company at A$12.69M.

Revenue
A$42.00K
-98.2% vs. a year earlier
EPS, diluted
-0.04 AUD
FY2025

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025

Valuation

Market cap
A$12.69M
P/E ratio
–
Price to sales
302.09
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
A$42.00K
Net income
-A$20.70M
EPS, diluted
-0.04 AUD

Trading

Previous close
$5.60
Open
$5.60
Day's range
$5.20 – $5.85
Volume
650,852
Average volume (20 days)
261,170
RSI (14 days)
23.7
Volatility (1 year)
128.3%
Relative volume
2.49×

Market cap history

Month-end market cap since 2016, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodKZIAS&P 500DifferenceKZIA per yearS&P 500 per year
1 month-26.8%-4.0%−22.7 pts
3 months-60.8%-5.0%−55.9 pts
Year to date-22.9%+8.2%−31.2 pts
1 year-12.7%+11.2%−23.9 pts
3 years-87.1%+68.5%−155.6 pts-49.4%+19.0%
5 years-99.1%+67.3%−166.4 pts-60.8%+10.8%
10 years-98.4%+291.6%−390.1 pts-34.0%+14.6%

Eleven years at a glance

Fiscal years 2015 to 2025, AUD

Revenue

A$42.00K-98.2% YoY

Net income

-A$20.70M

EPS, diluted

-0.04 AUD

Free cash flow

–
Reported period

Press releases

Releases Kazia Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Kazia Therapeutics

Pharmaceutical Preparations

Kazia Therapeutics Limited is a clinical-stage biotechnology company that focuses on the development of anti-cancer drug candidates. The company directs its operations toward targeted cancer therapies, concentrating on core pipeline assets including paxalisib, an investigational treatment for brain cancers and solid tumors, and EVT801, a selective VEGFR-3 inhibitor, alongside research associated with cantrixil. Kazia commercializes and advances its pipeline by partnering with international pharmaceutical and biotechnology enterprises through commercial and territory-based licensing agreements.

Company profile, executives and history

Kazia Therapeutics stock: common questions

What is Kazia Therapeutics's stock price?

KZIA closed at $5.31 on Nov 17, 2026, down 5.18% on the day.

What is Kazia Therapeutics's market cap?

Kazia Therapeutics was worth $8.60M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is KZIA's P/E ratio?

Kazia Therapeutics lost money over fiscal 2025 (diluted EPS -0.04 AUD), so it has no meaningful P/E ratio.

How much revenue does Kazia Therapeutics make?

Kazia Therapeutics reported revenue of A$42.00K for fiscal 2025, down 98.2% from a year earlier.

Does Kazia Therapeutics pay a dividend?

No. Kazia Therapeutics has not paid a cash dividend over the last twelve months.

How has KZIA stock performed over the past year?

Including dividends, KZIA returned -12.7% over the past year, against +11.2% for the S&P 500.

Who are Kazia Therapeutics's competitors?

Companies most similar to Kazia Therapeutics by business, industry and size include CNBX, NTHI, LSTA, KPRX, IXHL.

See a number that looks wrong?